A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Inclusion Criteria: * PRE-REGISTRATION ELIGIBILITY CRITERIA: * Histologically confirmed glioblastoma (World Health Organization \[WHO\] grade IV) presenting at first or second recurrence including secondary glioblastoma * Glioblastoma IDH-wildtype central nervous system (CNS) WHO grade 4 * Diffuse, astrocytic glioma IDH-wildtype with one or more of the following histological or genetic features: microvascular proliferation, necrosis, TERT promoter mutation, EGFR gene amplification, +7/-10 chromosome copy-number changes * Astrocytoma, IDH-mutant CNS WHO grade 4 * Diffuse astrocytic glioma IDH-mutant (with frequent ATRX and/or TP53 mutation and absence of 1p/19q codeletion), with necrosis and/or microvascular proliferation or one with lower grade histological features displaying homozygous deletion of CDKN2A and/or CDKN2B * NOTE: The eligibility criteria were changed to include the new diagnostic language from the WHO 2021 pathology classification change. The above diagnoses therefore reflect the change and include the entities that were previously eligible but now carry updated pathologic classification * Presence of measurable disease, as defined by a bidimensionally measurable lesion on magnetic resonance imaging (MRI) with a minimum diameter of 10 mm in both dimensions, prior to resection or biopsy of recurrent tumor * Tissue available from surgical resection or biopsy of recurrent tumor =\< 28 days prior to pre-registration, or planned surgery or biopsy o…